LUNAC Therapeutics are developing a first-in-class, next generation oral anticoagulant for the treatment and prevention of life-threatening thrombotic events, without the bleeding risk associated with current anticoagulants.
Their focus is on the inhibition of activated Factor XII (FXIIa), a clotting factor enzyme which plays a key role in pathological clot formation (thrombosis) but not in the stemming of bleeding (haemostasis).
We collaborated with LUNAC Therapeutics on a project awarded £3.14 million under Innovate UK’s Biomedical Catalyst programme, to develop a next-generation anticoagulant – read the press release.
